Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xeloda capecitabine: Interim Phase II data

Interim data from the open-label Phase II XeNA trial in newly diagnosed patients with invasive breast cancer showed

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE